AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray.
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 2, 2018|
|Previous Article:||Illumina price target raised to $380 from $350 at Piper Jaffray.|
|Next Article:||In hard Brexit, BMW would raise Dutch production, Reuters reports.|